Managing pandemic-driven dry eye with nutrition

Peter J. Polack, MD, FACS, of Ocala Eye, discusses how proper patient education and nutrition have been key to managing an increase in dry eye patients during the pandemic.

See the first segment of this interview:

COVID-19: Year in the life of ophthalmology practice

---

See more dry eye content

Watch more MJH Broadcasts

Related Videos
Doctor Esen Akpeck from the Wilmer Eye Institute, Johns Hopkins University School of Medicine.
Moving beyond the drop: CEO provides updates on Oyster Point's pipeline
Trukera Medical rebranding allows team to expand into the broader corneal health market
Post hoc analysis of varenicline solution OC-01 shows promise for dry eye patients undergoing anticholinergic therapy
Related Content

BNS Ophthalmics created to leverage nanotechnology in the development of ophthalmic pharmaceutical products.

June 9th 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

OKYO Pharma announces dosing of first patient in randomized portion of phase 2 trial of OK-101

June 8th 2023

Reflecting on life during a pandemnic

June 14th 2021

Peptide therapeutics are being introduced into ophthalmology

May 30th 2023

Additional death and reports of vision loss attributed to tainted eye drops

May 23rd 2023

BNS Ophthalmics created to leverage nanotechnology in the development of ophthalmic pharmaceutical products.

June 9th 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

OKYO Pharma announces dosing of first patient in randomized portion of phase 2 trial of OK-101

June 8th 2023

Reflecting on life during a pandemnic

June 14th 2021

Peptide therapeutics are being introduced into ophthalmology

May 30th 2023

Additional death and reports of vision loss attributed to tainted eye drops

May 23rd 2023

BNS Ophthalmics created to leverage nanotechnology in the development of ophthalmic pharmaceutical products.

June 9th 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

OKYO Pharma announces dosing of first patient in randomized portion of phase 2 trial of OK-101

June 8th 2023

Reflecting on life during a pandemnic

June 14th 2021

Peptide therapeutics are being introduced into ophthalmology

May 30th 2023

Additional death and reports of vision loss attributed to tainted eye drops

May 23rd 2023
© 2023 MJH Life Sciences

All rights reserved.